<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555434</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-NASH</org_study_id>
    <nct_id>NCT04555434</nct_id>
  </id_info>
  <brief_title>Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH</brief_title>
  <official_title>Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in Patients With Nonalcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chuncheon Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chuncheon Sacred Heart Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study for evaluating the improvement effect of non-alcoholic steatohepatitis (NASH) of&#xD;
      probiotics&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-alcoholic fatty liver disease progresses to fatty liver, hepatitis, cirrhosis, and liver&#xD;
      cancer, resulting in a high mortality rate. The prevalence of non-alcoholic fatty liver&#xD;
      disease at home and abroad is a major social and economic burden. However, there is no cure&#xD;
      for non-alcoholic fatty liver disease. Recently, intestinal axis theory related to the&#xD;
      development of chronic liver disease and microbial community has emerged. Intake of&#xD;
      probiotics is known to play a role in regulating gut microflora. Improvement of non-alcoholic&#xD;
      fatty liver disease can be expected through administration of probiotics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">September 11, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 11, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Evaluates the effect of probiotic improvement on non-alcoholic fatty liver disease in patients diagnosed with non-alcoholic fatty liver disease.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demographic characteristics</measure>
    <time_frame>1 week</time_frame>
    <description>The gender, date of birth, age, menstruation, and amenorrhea, FAMILY HISTORY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Outcomes; Liver Function Test</measure>
    <time_frame>Baseline of AST, ALT, rGT, CHOL, and ALP at first week.</time_frame>
    <description>Primary outcomes of liver function enzyme level (AST, ALT, rGT, CHOL, ALP)[IU/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gut-Microbiome Composition</measure>
    <time_frame>Change from Baseline of fecal microbiome at 8 months</time_frame>
    <description>Change of the species and proportions of the gut microbiome. Proportion of phyrum level Composition of F/B ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Computed Tomography</measure>
    <time_frame>Change from Baseline of CT image at 8 months</time_frame>
    <description>change of the Abdominal ultrasonography or Computed Tomography(CT): Upper abdominal ultrasound or CT to determine the degree of fatty liver disease&#xD;
② Fibroscan: Objectively and quantitatively grasp the degree of liver fibrosis by measuring the degree of firmness (elasticity) of the liver</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change of BMI</measure>
    <time_frame>Change from Baseline BMI and weight at 6 months</time_frame>
    <description>Compare the body mass index. BMI=Body Weight/(Height)^2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Secondary Outcomes; Liver Function Test</measure>
    <time_frame>Change from Baseline of AST, ALT, rGT, CHOL, and ALP at 8 months</time_frame>
    <description>Secondary outcomes of liver function enzyme level (AST, ALT, rGT, CHOL, ALP)[IU/L]</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Probiotics group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The selected test subjects were randomly assigned to test group 1, test group 2, test group 3, or control group according to the order registered at visit 2 (week 0) after a 2-week run-in period, and for 8 weeks, the study drug or study After taking the treaty, analyze the results of the observations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The selected test subjects were randomly assigned to test group 1, test group 2, test group 3, or control group according to the order registered at visit 2 (week 0) after a 2-week run-in period, and for 8 weeks, the study drug or study After taking the treaty, analyze the results of the observations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>Experimental group Main ingredients: P. pentosaceus KID7, L. lactis CKDB001 or L. helveticus CKDB001 (containing 9 × 10^9 CFU / day)&#xD;
Control group Main ingredient: Crystalline cellulose</description>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>Probiotics group</arm_group_label>
    <other_name>Cellulose (Placebo)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Those who agreed to participate in this study and signed a written consent&#xD;
&#xD;
          2. Adult men and women over 20&#xD;
&#xD;
          3. Patients diagnosed with non-alcoholic fatty liver&#xD;
&#xD;
             ※ Exclusion criteria for alcoholic liver disease&#xD;
&#xD;
               -  Those who have an alcoholic drinking ability of at least 60g per day for at least&#xD;
                  one year before visiting (30g for women)&#xD;
&#xD;
               -  1 bottle of shochu 360 ml * 20% = 72 g, 1 bottle of beer 500 ml (330 ml for&#xD;
                  commercial use) * 5% = 25 (16.5 g)&#xD;
&#xD;
          4. Patients with higher liver numbers than normal ※ Adult normal liver level range by&#xD;
             enzyme&#xD;
&#xD;
               -  AST, ALT: 40 or less&#xD;
&#xD;
               -  ALP: 20-130&#xD;
&#xD;
               -  GOT: 0-30, GPT: 0-38&#xD;
&#xD;
               -  GGT: 10-62 (male), 7-35 (female)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who have consumed probiotics (lactic acid bacteria, etc.), prebiotics (dietary&#xD;
             fiber, fructooligosaccharide, etc.), new biotics, fermented milk, etc. within the past&#xD;
             month.&#xD;
&#xD;
          2. Those who have continuously taken antibiotics within the last 2 months or who are&#xD;
             likely to take them during the study period&#xD;
&#xD;
          3. Those who have continuously consumed medicines or health functional foods that affect&#xD;
             liver function within the past month.&#xD;
&#xD;
          4. Those who have participated in other clinical trials within the past 1 month (but not&#xD;
             applicable to medical device clinical trials)&#xD;
&#xD;
          5. If you have any of the following&#xD;
&#xD;
               -  Alcoholic liver disease, hereditary metabolic disease, autoimmune hepatitis&#xD;
&#xD;
               -  systemic inflammatory disease or immune disease&#xD;
&#xD;
               -  Hepatocellular carcinoma&#xD;
&#xD;
               -  Uncontrolled cardiopulmonary disease&#xD;
&#xD;
               -  Other serious systemic disorders in the heart, lungs, blood, and endocrine system&#xD;
&#xD;
          6. A person with a history of malignancy diagnosis within the last 5 years&#xD;
&#xD;
          7. Pregnant or lactating women&#xD;
&#xD;
          8. Persons who have hypersensitivity to the test drug / placebo or components contained&#xD;
             in the test drug / placebo or have severe allergic reactions&#xD;
&#xD;
          9. Those who are not suitable for the clinical trial because the investigator judges&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>62 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ki Tae Suk, Professor</last_name>
    <phone>+82-10-5365-5700</phone>
    <email>ktsuk@hallym.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hallym University Chuncheon Sacred Heart Hospital</name>
      <address>
        <city>Chuncheon</city>
        <state>Gangwon</state>
        <zip>200-704</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Tae Suk</last_name>
      <phone>+82-10-5365-5700</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Liver disease</keyword>
  <keyword>Gut microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

